UCSF Memory and Aging Center
Welcome,         Profile    Billing    Logout  
 14 Trials 
38 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Geschwind, Michael
CT-AMT-130-01, NCT04120493: Safety and Proof-of-Concept (POC) Study with AMT-130 in Adults with Early Manifest Huntington's Disease

Hourglass Jan 2021 - Dec 2021 : Early efficacy data on initial patients for Huntington's disease
Checkmark First biomarker data from trial for Huntington’s disease
Nov 2021 - Nov 2021: First biomarker data from trial for Huntington’s disease
Checkmark Safety data from P1/2 trial for Huntington’s disease
Feb 2021 - Feb 2021: Safety data from P1/2 trial for Huntington’s disease
Recruiting
1/2
37
US
intra-striatal rAAV5-miHTT, AMT-130, Imitation (sham) surgery
UniQure Biopharma B.V.
Huntington's Disease
04/29
06/29
NCT03487367: Clinical Trial Readiness for SCA1 and SCA3

Active, not recruiting
N/A
200
US
The Methodist Hospital Research Institute, University of Michigan, University of Minnesota, University of Utah, University of California, Los Angeles, University of Chicago, University of South Florida, Harvard University, Johns Hopkins University, University of Florida, Columbia University, Emory University, University of California, San Francisco, University of Alabama at Birmingham, University of Colorado, Denver, University of Rochester, Stanford University, Northwestern University, German Center for Neurodegenerative Diseases (DZNE), Institut de Recherche sur la Moelle épinière et l'Encéphale, University of Pennsylvania, Ohio State University, University of Iowa
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia 3
12/23
12/23
NCT01060371: Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Recruiting
N/A
800
US
All Participants
University of Florida, National Ataxia Foundation, University of California, Los Angeles
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6
05/24
05/24
CADASIL, NCT05677880: Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy () Study

Recruiting
N/A
500
US
Study Procedures
University of Wisconsin, Madison, National Institute on Aging (NIA)
CADASIL
01/26
01/26
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting
N/A
35000
Europe, Canada, US, RoW
CHDI Foundation, Inc.
Huntington's Disease
01/62
01/62
Boxer, Adam L
NCT03260920: Intranasal Oxytocin for Frontotemporal Dementia

Active, not recruiting
2
112
Canada, US
Syntocinon, Intranasal Oxytocin
Lawson Health Research Institute, Weston Brain Institute, Canadian Institutes of Health Research (CIHR), Berry Consultants
Frontotemporal Dementia
06/23
12/24
SAL-AD, NCT03277573: Salsalate in Patients Mild to Moderate Alzheimer's Disease

Active, not recruiting
1b
40
US
Salsalate, Placebo
Adam Boxer
Alzheimer Disease
04/21
12/21
4RTNI-2, NCT02966145: 4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

Active, not recruiting
N/A
232
Canada, US
Observational Study
University of California, San Francisco, National Institutes of Health (NIH), National Institute on Aging (NIA)
Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)
12/24
12/24
4RTNI, NCT01804452: 4 Repeat Tauopathy Neuroimaging Initiative

Active, not recruiting
N/A
110
US
Observational Study
University of California, San Francisco, National Institutes of Health (NIH), National Institute on Aging (NIA)
Progressive Supranuclear Palsy, Corticobasal Degeneration
12/24
12/24
NCT04363684: ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Recruiting
N/A
2100
Canada, US
Mayo Clinic, University of California, San Francisco, National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS)
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
06/25
06/25
NCT06774183: Effect of Presbyopia Correction on Livelihood and Repayment Among Solar Customers in Western Region, Kenya

Not yet recruiting
N/A
1085
NA
Near vision glasses for presbyopia correction
Dot Glasses Kenya, Queen's University Belfast, UK, University of Stellenbosch, Sun King, Livelihood Impact Fund
Presbyopia Correction, Visual Impairment and Blindness (Excl Colour Blindness), Repayment Behaviour, Livelihoods
08/25
09/25
NCT04516499: Neurofilament Surveillance Project (NSP)

Active, not recruiting
N/A
342
US
The Bluefield Project to Cure Frontotemporal Dementia, Mayo Clinic, University of California, San Francisco
Frontotemporal Dementia, Frontotemporal Lobar Degeneration, FTD-GRN, FTD, FTLD
02/27
02/27
Moskowitz, Judith
NCT05394051: Psychological Well-being and Burnout in Healthcare Workers During the COVID-19 (Coronavirus Disease 2019) Pandemic

Active, not recruiting
N/A
555
US
Positive Affect Regulation sKills (PARK), PARK
Northwestern University
COVID-19, Burnout, Burnout, Professional, Work-related Illness, Work-Related Stress, SARS-CoV-2 Infection
05/23
03/24
PARK-NU, NCT04367922: Positive Affect Regulation sKills at Northwestern University

Completed
N/A
1000
US
Positive Emotion Skills Course
Northwestern University
Anxiety, Depression, Social Isolation
12/23
12/23
NCT03610698: Life Enhancing Activities for Family Caregivers (LEAF 2.0)

Completed
N/A
386
US
LEAF Positive Emotion Intervention, Emotion Reporting Control Condition
Northwestern University, University of California, San Francisco
Caregivers
09/24
09/24
MOST EMPOWER, NCT04317417: Optimizing An Emotion Regulation Intervention

Active, not recruiting
N/A
352
US
EMPOWER
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Cancer
03/25
03/25
SAGE LEAF 2, NCT06708182: An Online Program to Reduce Dementia Caregiver Burden

Not yet recruiting
N/A
140
US
SAGE LEAF Positive Emotion Skills Course
Northwestern University, National Institute on Aging (NIA), BrightOutcome, Inc.
Caregiving Stress, Caregiver Burden
06/26
06/26
FOREST, NCT05942469: Fostering Optimal Regulation of Emotion for Prevention of Secondary Trauma

Not yet recruiting
N/A
100
US
FOREST
Northwestern University
Burnout, Burnout, Professional, Positive Affect, Depression, Anxiety, Compassion Fatigue, Job Stress
08/26
08/26
Sturm, Virginia E
NCT05152992: Spatiotemporal Dynamics of the Human Emotion Network

Enrolling by invitation
N/A
100
US
Viewing visual stimuli and electrical stimulation of the brain
University of California, San Francisco, San Francisco State University, National Institute of Mental Health (NIMH)
Epilepsy, Depression, Anxiety, Emotions
06/26
06/26
Koestler, Mary
NCT03260920: Intranasal Oxytocin for Frontotemporal Dementia

Active, not recruiting
2
112
Canada, US
Syntocinon, Intranasal Oxytocin
Lawson Health Research Institute, Weston Brain Institute, Canadian Institutes of Health Research (CIHR), Berry Consultants
Frontotemporal Dementia
06/23
12/24
Ljubenkov, Peter
INFRONT-3, NCT04374136 / 2019-004066-18: A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia

Active, not recruiting
3
110
Europe, Canada, US, RoW
AL001, Placebo, Open label - AL001
Alector Inc.
Frontotemporal Dementia
09/25
10/27
ROCKIT-1, NCT04734379: Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

Active, not recruiting
2a
15
US
Fasudil
Woolsey Pharmaceuticals
Progressive Supranuclear Palsy, Corticobasal Syndrome
11/22
11/23
NCT04993755 / 2021-002251-11: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Active, not recruiting
2a
42
Europe, US
TPN-101, 400 mg/day, Placebo
Transposon Therapeutics, Inc., Transposon Therapeutics, Inc
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
09/23
09/23
INFRONT-2, NCT03987295 / 2019-000138-20: A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients

Completed
2
33
Europe, Canada, US
AL001
Alector Inc., GlaxoSmithKline
Frontotemporal Dementia
06/24
06/24
Veri-T-001, NCT05184569: Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

Recruiting
1
64
US
Verdiperstat, BHV-3241
Peter Ljubenkov, MD, National Institutes of Health (NIH), Alzheimer's Association, National Institute on Aging (NIA)
Semantic Dementia
06/26
09/26
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
Glueck, Julia
NCT01060371: Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Recruiting
N/A
800
US
All Participants
University of Florida, National Ataxia Foundation, University of California, Los Angeles
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6
05/24
05/24
Snowberg, Karin
Veri-T-001, NCT05184569: Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

Recruiting
1
64
US
Verdiperstat, BHV-3241
Peter Ljubenkov, MD, National Institutes of Health (NIH), Alzheimer's Association, National Institute on Aging (NIA)
Semantic Dementia
06/26
09/26
NCT06036251: COVID-19 Pandemic Induced Stress and Symptoms

Completed
N/A
415
US
Questionnaires
University of California, San Francisco
Stress Reaction, Stress, Emotional, Stress, COVID-19 Pandemic
04/23
04/23
VandeVrede, Lawren
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
4RTNI-2, NCT02966145: 4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

Active, not recruiting
N/A
232
Canada, US
Observational Study
University of California, San Francisco, National Institutes of Health (NIH), National Institute on Aging (NIA)
Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)
12/24
12/24
QUIP II, NCT06025877: Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

Recruiting
N/A
400
US
PrecivityAD2(TM) blood test, AD2
C2N Diagnostics
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Impairment, Memory Impairment
04/25
04/25
Sulse, Tayler
Veri-T-001, NCT05184569: Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

Recruiting
1
64
US
Verdiperstat, BHV-3241
Peter Ljubenkov, MD, National Institutes of Health (NIH), Alzheimer's Association, National Institute on Aging (NIA)
Semantic Dementia
06/26
09/26
Jacobs, Leslie M
QUIP II, NCT06025877: Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

Recruiting
N/A
400
US
PrecivityAD2(TM) blood test, AD2
C2N Diagnostics
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Impairment, Memory Impairment
04/25
04/25
Yang, Xueyi
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Recruiting
2
220
Europe, US
FNP-223, Placebo
Ferrer Internacional S.A.
Progressive Supranuclear Palsy
11/26
11/26
Veri-T-001, NCT05184569: Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

Recruiting
1
64
US
Verdiperstat, BHV-3241
Peter Ljubenkov, MD, National Institutes of Health (NIH), Alzheimer's Association, National Institute on Aging (NIA)
Semantic Dementia
06/26
09/26
Leahy, Cara
QUIP II, NCT06025877: Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

Recruiting
N/A
400
US
PrecivityAD2(TM) blood test, AD2
C2N Diagnostics
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Impairment, Memory Impairment
04/25
04/25

Download Options